What are Clopidogrel Ir Dc Granules 0.25 Pellets?

Clopidogrel Ir Dc Granules 0.25 Pellets are a pharmaceutical granule or pellet product identified by the supplied name as containing clopidogrel and having an IR DC designation. The meaning of “0.25” and the exact granule composition, drug loading, release characteristics and intended manufacturing application require confirmation from the supplier’s technical specification before use in formulation development.

Uses / Applications

Subject to confirmation of the product specification, this material may be intended for pharmaceutical formulation and further processing.

Potential applications include:

• Use as an intermediate in the manufacture of an appropriate clopidogrel-containing finished dosage form.

• Incorporation into a validated pharmaceutical formulation where the material’s composition and specifications are suitable.

• Pharmaceutical development involving clopidogrel granules or pellets.

Therapeutic context: Clopidogrel is an antiplatelet medicine used to reduce platelet aggregation in certain cardiovascular conditions. This therapeutic context does not establish that the supplied granules are approved for direct patient administration.

6. Benefits

Potential formulation considerations include:

• Defined product identity: The supplied name identifies clopidogrel as the active ingredient.

• Granule or pellet presentation: The material is described as granules and pellets in the product name.

• IR designation: The name indicates immediate-release, subject to verification.

• Pharmaceutical sourcing support: Kelar Pharmachem India is a pharmaceutical sourcing and export company supporting international pharmaceutical supply requirements.

The drug loading, particle-size distribution, content uniformity, dissolution performance and compatibility with manufacturing processes must be confirmed through the applicable technical documentation. No product-specific performance advantage is assumed.

7. Side Effects

Patient-level adverse effects cannot be determined from the granule or pellet dosage form alone. They depend on the active ingredient, final formulation, dose, route of administration and approved product information.

Clopidogrel-containing finished medicines may increase the risk of bleeding. Other reported adverse effects can include bruising, nosebleeds, gastrointestinal discomfort and diarrhoea. Serious bleeding and rare blood-related complications are also recognised risks of clopidogrel therapy.

This information describes the active ingredient’s general clinical safety profile and is not a claim that the supplied intermediate is intended for direct administration.

8. How Does It Work?

Formulation mechanism: The supplied product name includes “IR”, which commonly denotes immediate-release. The meaning of “DC” and the formulation technology used in these granules have not been confirmed. The release behaviour should be checked against the technical specification.

Pharmacological mechanism: Clopidogrel is a prodrug that is converted into an active metabolite. This metabolite inhibits platelet P2Y12 ADP receptors, reducing platelet activation and aggregation and helping prevent the formation of harmful blood clots in appropriate clinical settings.

9. Dosage Guidelines / Processing Instructions

For pharmaceutical intermediates, incorporation quantities must be established using the confirmed clopidogrel content, the target strength of the finished medicine and the approved formulation specifications.

• Confirm the meaning and unit of “0.25”.

• Verify the active ingredient content and applicable assay basis.

• Confirm the intended meaning of “IR DC” with the supplier.

• Establish manufacturing parameters through appropriate formulation development and validation.

• Follow the applicable technical documentation and quality-control procedures.

No patient dosage or manufacturing parameters can be recommended from the product name alone. Do not assume the granules or pellets can be swallowed directly, crushed, chewed or mixed with food.

10. When Not to Use

For pharmaceutical intermediates, suitability should be assessed against the approved material specification, quality requirements and intended manufacturing process.

Do not use the material if its identity, active ingredient content or quality status cannot be adequately verified.

For finished clopidogrel medicines, contraindications must be assessed using the approved prescribing information. These may include active pathological bleeding, such as a peptic ulcer bleed or intracranial haemorrhage, and hypersensitivity to clopidogrel or product components.

11. Drug / Product Interactions

For formulation development, compatibility with excipients and other active ingredients must be established through suitable testing.

For finished clopidogrel medicines, clinically important considerations include:

• Anticoagulants and other antiplatelet medicines: May increase bleeding risk.

• Non-steroidal anti-inflammatory drugs (NSAIDs): May increase bleeding risk, including gastrointestinal bleeding.

• Some proton pump inhibitors: Omeprazole and esomeprazole can reduce the formation of clopidogrel’s active metabolite and may affect its antiplatelet activity.

• Other interacting medicines: Must be assessed against the approved prescribing information.

These are clinical considerations for finished medicines, not confirmed compatibility findings for the supplied granules.

12. Safety Advice

• Handle the material according to the applicable safety data sheet and technical documentation.

• Verify the product identity, batch information and active ingredient content before use.

• Follow the receiving manufacturer’s quality and material-handling procedures.

• Review the certificate of analysis and applicable technical specifications, where available.

• Do not assume that the material is suitable for direct patient administration.

• For finished clopidogrel medicines, bleeding risk and other precautions should be assessed by a qualified healthcare professional.

13. General Instructions

• Verify the complete product name and the meaning of “0.25”.

• Confirm the intended granule or pellet specification with the supplier.

• Inspect the packaging for damage or contamination.

• Request the technical data sheet and applicable certificate of analysis, subject to availability.

• Maintain appropriate batch traceability and quality-control records.

• Follow the documented handling, processing and storage requirements.

14. Special Dietary / Lifestyle Tips

Dietary and lifestyle advice is generally not applicable to pharmaceutical intermediates. For patients using a finished clopidogrel medicine, lifestyle guidance should be based on the underlying cardiovascular condition and advice from a qualified healthcare professional. Patients should not stop prescribed antiplatelet treatment without medical advice.

15. Comparison with Other Formulations

These are general formulation distinctions; no comparative superiority or product-specific performance has been established.

16. Precautions & Warnings

• Confirm the meaning and unit of “0.25” before calculating formulation quantities.

• Verify the active ingredient content and release characteristics.

• Do not assume a particular coating, particle-size distribution or dissolution profile.

• Establish compatibility with the intended formulation and manufacturing process.

• Follow the applicable technical documentation and quality requirements.

• For finished clopidogrel medicines, consider the clinically significant risk of bleeding and relevant drug interactions.

17. Can I Use It With Other Medicines or Ingredients?

Compatibility with other active ingredients and excipients must be established through formulation development and appropriate testing. The supplied product name does not confirm compatibility with any particular material or manufacturing process.

For finished clopidogrel medicines, concomitant use with anticoagulants, other antiplatelet medicines, NSAIDs or interacting medicines requires assessment using the approved prescribing information and advice from a qualified healthcare professional.

18. Storage

Store according to the manufacturer’s approved product specifications and technical documentation. Refer to the product packaging or applicable technical data sheet for the required storage conditions.

19. Frequently Asked Questions (FAQs)

1. What are Clopidogrel IR DC Granules 0.25 Pellets?

They are a pharmaceutical granule or pellet product identified by the supplied name as containing clopidogrel. The exact composition and intended application require confirmation.

2. What is the active ingredient?

The stated active ingredient is clopidogrel.

3. What does “0.25” mean?

The supplied product name does not specify whether 0.25 refers to a percentage, drug loading, strength or another measurement. The unit and basis should be confirmed with the supplier.

4. What does IR mean?

IR commonly stands for immediate-release. The product’s actual release performance should be confirmed against its technical specification.

5. What does DC mean in the product name?

The abbreviation DC has not been defined in the supplied information. It should be clarified with the supplier rather than assigned an unverified technical meaning.

6. Are these granules intended for direct administration?

Direct administration suitability has not been established. Confirm the intended application and product-specific instructions before use.

7. Is a technical data sheet available?

The technical data sheet is listed as available upon request. Availability and document contents should be confirmed with the supplier.

8. Can Kelar Pharmachem India support export enquiries?

Kelar Pharmachem India is a pharmaceutical sourcing and export company. Product specifications, documentation, packing and supply availability should be confirmed for the specific enquiry.